Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

FY21 Q3: Is Volpara (ASX:VHT) the best healthcare share?

The Volpara Health Technologies Ltd (ASX:VHT) share price could rise today after an impressive FY21 third quarter update.

The Volpara Health Technologies Ltd (ASX: VHT) share price could rise today after an impressive FY21 third quarter update.

Volpara’s software is used for screening clinics to provide feedback on breast density, compression, dose and quality. Its enterprise-wide practice management software helps with productivity, compliance, reimbursement and patient tracking.

FY21 Q3 update

The healthcare ASX share announced its best ever third quarter sales performance. Annual recurring revenue (ARR) rose by 20% to NZ$20.7 million, driven by an increasing demand for the Volpara breast health platform.

The average revenue per user (ARPU) went up 5% from the FY21 second quarter to US$1.22. ARPU for deals ranged from US$1.43 for a single product to US$5.12 for multi-product bundles, with some smaller volume deals above that range.

Volpara said that its customer churn remains low and US coverage remains at approximately 27%.

Volpara said that it received strong quarterly cash receipts from customers of NZ$4.6 million despite COVID-19 and the weaker US dollar. This was up 2%. Cash receipts for the nine months to December 2020 were up 20%.

The company received its first payment from the partnership with a genetics company.

Management comments

Volpara CEO Dr Ralph Highnam said: “It has been a truly remarkable sales quarter, with a set of outstanding new deals coming over the line and growing our recurring revenue significantly, despite COVID-19. Very encouragingly, our ability to identify women at high cancer risk who should have genetics testing has potential to be a game-changer and significantly increase our ARPU. Over the next few quarters, our focus will be on ramping those genetics relationships and connections as quickly as we can.”

Summary thoughts

Volpara is a really good business with a very high profit margin and steadily rising revenue. That’s a good combination, particularly with its retention rate being so high, growing ARPU and it’s winning more clients.

The ASX healthcare share looks like one to watch. There are other ASX growth shares that I like the look of such as Pushpay Holdings Ltd (ASX: PPH) and Magellan Financial Group Ltd (ASX: MFG).

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content